OLD Category: signatures

Everolimus plus Exemestane for Hormone Receptor‐Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO‐2

• Prat A et al.,

Application of the Transcriptional Disease Signature (TDSs) to Screen Melanoma-Effective Compounds in a Small Fish Model

• Lu Y. et. al.,

Polypropylene mesh implantation for hernia repair causes myeloid cell–driven persistent inflammation

• Heymann F et al.,

First‐in‐human, phase I study of PF‐06647263, an anti‐EFNA4 calicheamicin antibody–drug conjugate, in patients with advanced solid tumors

• Garrido‐Laguna I et al.,

Modulation of temozolomide dose differentially affects T-cell response to immune checkpoint inhibition

• Karachi A. et al.,

Modulation of Inflammation-Related Genes in the Cornea of a Mouse Model of Dry Eye upon Treatment with Cyclosporine Eye Drops

• Daull P. et al.,

Lymphocyte Antigen 6 Complex, Locus C+ Monocytes and Kupffer Cells Orchestrate Liver Immune Responses Against Hepatitis B Virus in Mice

• Wu LL et al.,

Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases

• Volckmar RL et al.,

Quantitative immunohistochemical assay with novel digital immunostaining for comparisons of PD-L1 antibodies

• Fujisawa T et al.,

Microtubules Deform the Nuclear Membrane and Disrupt Nucleocytoplasmic Transport in Tau-Mediated Frontotemporal Dementia

• Paonessa F et al.,

Sex and Pubertal Differences in the Type 1 Interferon Pathway Associate With Both X Chromosome Number and Serum Sex Hormone Concentration

• Webb K et al.,

Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma

• Gartrell RD et al.,